This Biotech with Breakout MS Drug Draws Big Investment
A breakout multiple sclerosis drug can change a biotech's trajectory. This article digs into an $8 million investment...
Tax harvesting to lower capital gains automates selling decisions to reduce taxes while maintaining portfolio goals.
25,625 articlesA breakout multiple sclerosis drug can change a biotech's trajectory. This article digs into an $8 million investment...
July can bring clear catalysts for Disney stock investors. This guide highlights three dates to watch, explains why t...
As oil approaches the $100 threshold, major energy producers could boost dividends and buybacks. Here's which names c...
Investing in high-growth EV names can be tempting when share prices dip. This guide helps you evaluate should rivian ...
AST SpaceMobile has surged, leaving investors asking whether spacemobile buy, sell, hold makes sense now. This articl...
CoreWeave rode the AI compute wave, but headwinds have grown. This guide explains what's wrong with CoreWeave, the co...
As Rex gears up to report Q4 2025 results, investors should focus on growth drivers, margins, and the outlook. This g...
After a dramatic fall, Canopy Growth has staged a cautious comeback. This article breaks down whether canopy growth s...
Unpack GEO Group's Q1 2026 earnings through the transcript lens. Learn what drove revenue, how margins held up, and w...
SpaceX is growing fast, but its financing moves could change the risk profile for investors. This article breaks down...
A first-look at Vaalco Energy 2026 earnings, what Q1 results might reveal about production, cash flow, and risk. Lear...
Investors weighing Dow and LYB face a crossroads in 2026. This guide breaks down business models, catalysts, risks, a...